Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (323)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Apply filters
Showing 271 to 280 of 323
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441
Technology appraisal guidance
TBC
Sipavibart for preventing COVID 19 [ID6282]
Technology appraisal guidance
TBC
Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]
Technology appraisal guidance
TBC
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Technology appraisal guidance
TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
Technology appraisal guidance
TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]
Technology appraisal guidance
19 March 2025
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Technology appraisal guidance
26 February 2025
Sparsentan for treating primary IgA nephropathy [ID6308]
Technology appraisal guidance
30 April 2025
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Technology appraisal guidance
21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
Technology appraisal guidance
TBC
Previous page
1
…
26
27
Current page
28
29
30
…
33
Page
28
of
33
Next page
Results per page
10
25
50
All
Back to top